News
OXFD
--
0.00%
--
PerkinElmer Completes Acquisition of Oxford Immunotec Global PLC
PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today announced that the Company has completed its previously announced acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). PerkinElmer originally anno...
BusinessWire · 03/09 13:00
News On Oxford Immunotec Global PLC (OXFD) Now Under PKI
News On Oxford Immunotec Global PLC (OXFD) Now Under PKI
Dow Jones · 03/08 22:08
Shares of OXFD Up 62.9% Since Uptrend Call on Shares
Mar 05, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Oxford Immunotec (NASDAQ:OXFD) on November 5th, 2020 at $13.49. In...
marketwatch.com · 03/05 05:33
Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection
Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company, announced that today it has released the T-SPOT.COVID test, a CE marked ELISPOT based test intended for qualitative detection of a cell mediated (T cell)...
PR Newswire · 03/04 20:01
PerkinElmer, Inc. -- Moody's assigns Baa3 rating to PerkinElmer's notes offering
Rating Action: Moody's assigns Baa3 rating to PerkinElmer's notes offeringGlobal Credit Research - 04 Mar 2021New York, March 04, 2021 -- Moody's Investors Service, ("Moody's") assigned a Baa3 rating to the proposed offering of senior unsecured 10- and 30-...
Moody's · 03/04 15:09
Fitch Rates PerkinElmer's Unsecured Notes 'BBB'
reuters.com · 03/04 14:24
8-K: Oxford Immunotec Global PLC
falseX00001586049NASDAQ00015860492021-02-262021-02-26 -------------------------------------------------------------------------------- UNITED STATES...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/27 08:06
Oxford Immunotec Has Returned 62.6% Since SmarTrend Recommendation (OXFD)
Feb 25, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Oxford Immunotec (NASDAQ:OXFD) on November 5th, 2020 at $13.49. In...
marketwatch.com · 02/25 18:01
Tuberculosis Diagnostics Market Growth Survey 2021 with Top Countries Data Industry Size, Share, Business Growth, Revenue, Trends, Market Demand Penetration and Forecast | With Covid 19 Analysis
The Express Wire · 02/24 02:49
Oxford Immunotec (OXFD) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Zacks.com · 02/22 17:30
Lyme Disease Diagnostic Devices Market is Exhibiting a CAGR of 7.2% By 2027
Feb 22, 2021 (Market Insight Reports) -- The Lyme Disease Diagnostic Devices Market size is forecast to exceed US$ 3.87 billion by 2027 and is projected to...
Market Insight Reports · 02/22 05:35
Oxford Immunotec Has Returned 62.7% Since SmarTrend Recommendation (OXFD)
Feb 18, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Oxford Immunotec (NASDAQ:OXFD) on November 5th, 2020 at $13.49. In...
marketwatch.com · 02/18 05:32
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - RP, CUB, CRHM, OXFD, FLIR, CBLI, AJRD
, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PR Newswire - PRF · 02/17 18:22
Shares of OXFD Up 63.0% Since Uptrend Call on Shares
SmarTrend identified an Uptrend for Oxford Immunotec (NASDAQ:OXFD) on November 5th, 2020 at $13.49. In approximately 3 months, Oxford Immunotec has returned 63.00% as of today's recent price of $21.98.
Comtex SmarTrend(R) · 02/10 17:56
Oxford signs MOU with Green Cross Medical for T-SPOT Discovery SARS-CoV-2 kit
Oxford Immunotec (OXFD) announces it has worked with Green Cross Medical Science South Korea (GC MS) to enter into an MOU to market the research use only T-SPOT Discovery SARS-CoV-2 kit in South Korea.Under the
Seekingalpha · 02/08 14:56
Oxford Immunotec Reports Deal With Green Cross Medical Science To Market T-SPOT Discovery SARS-CoV-2 Kit For Measurement Of T Cell Immune Response To Infection In South Korea
Oxford Immunotec Global PLC (NASDAQ:OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has worked with GC MS and MESDIA Co., Ltd. to enter into an MOU to market the research
Benzinga · 02/08 14:17
Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. - South Korea) to Market the T-SPOT(R) Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the "Company"), a global, high-growth diagnostics company today announces it has worked with GC MS and MESDIA Co., Ltd. to enter ...
Globe Newswire · 02/08 14:15
Lyme Disease Diagnostic Devices Market Growth Scenario, Industry Size, Share Analysis, Trends, Competitive Analysis and Global Forecasts to 2027
Feb 05, 2021 (Market Insight Reports) -- Canada – The global Lyme Disease Diagnostic Devices market size is projected to hit USD 3.87 billion by 2027 and...
Market Insight Reports · 02/05 07:30
Oxford Immunotec updates T-SPOT COVID-19 test kit with new panel
Oxford Immunotec ([[OXFD]] +0.2%) announces an update to the configuration of its T-SPOT Discovery SARS-CoV-2 kit to include a cross-reactive panel.An additional panel included in the kit contains epitopes of high genetic homology to endemic
Seekingalpha · 02/04 15:01
BRIEF-Oxford Immunotec Updates Their T-SPOT Discovery SARS-CoV-2 Kit, Include A New Panel To Detect T Cells Reactive To Endemic Coronaviruses
reuters.com · 02/04 14:21
Webull provides a variety of real-time OXFD stock news. You can receive the latest news about Oxford Immunotec through multiple platforms. This information may help you make smarter investment decisions.
About OXFD
Oxford Immunotec Global PLC,is a diagnostics company. It is focused on developing and commercializing tests for under-served immune-regulated conditions. Its product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Tick-borne disease is the collective name for diseases passed to humans through the bite of an infected tick. Its diagnostic tests for tick-borne infections include multiple laboratory developed tests (LDTs). Its tick-borne disease tests utilize molecular methods (such as polymerase chain reaction) and techniques to prosecute the immune system. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease.